Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed (histology) Squamous Cell Carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.~* No prior surgery, radiation therapy or chemotherapy of this tumor other than biopsy or emergency procedure required for supportive care.~* Clinically staged Stage II, III, or IVA cancer, assessed to be surgically resectable with curative intent.~* Life Expectancy of greater than 6 months~Exclusion Criteria:~* Stage IVB Squamous Cell Carcinoma~* Use of any investigational agent within the previous 30 days~* Uncontrolled cardiovascular disease~* Myocardial infarction within the last 3 months~* Abnormal hemoglobin, neutrophil, lymphocyte or platelet counts~* Positive for hepatitis B or C or HIV~* Evidence of distant metastases~* Clinical gastritis or peptic ulcer within the last 6 months~* Stroke within the last six months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IRX-2 Regimen (Type: EXPERIMENTAL): The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin, zinc supplementation, and omeprazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).